Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003325 · ClinicalTrials.gov registry record · Phase 3
Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva
A Phase 3 study of Vulvar Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 515
- Enrollment target
- 20
- Study locations
NCT00003325: Completed Phase 3 study of Vulvar Cancer, sponsored by Gynecologic Oncology Group.
NCT00003325 is a Phase 3 study of Vulvar Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 515 participants, above the 423-participant average among 17 other Vulvar Cancer trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003325, a Phase 3 study of Vulvar Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 515 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Lymphatic mapping may improve the ability to detect cancer of the vulva. PURPOSE: This phase III trial is studying how well lymphatic mapping works in treating patients with stage I or stage II cancer of the vulva.
Conditions Studied
Interventions
- PROCEDURE Sentinel lymph node mapping
Study Locations (20)
Indiana
- Elkhart General Hospital - Elkhart
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
- Gynecologic Oncology of Indiana - Indianapolis
- St. Vincent Indianapolis Hospital - Indianapolis
- Howard Community Hospital - Kokomo
- CCOP - Northern Indiana CR Consortium - South Bend
- Memorial Hospital of South Bend - South Bend
- Saint Joseph Regional Medical Center - South Bend
- South Bend Clinic - South Bend
Connecticut
- Helen and Harry Gray Cancer Center at Hartford Hospital - Hartford
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center - Hartford
- George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus - New Britain
California
- Todd Cancer Institute at Long Beach Memorial Medical Center - Long Beach
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Illinois
- Hinsdale Hematology Oncology Associates - Hinsdale
- Cardinal Bernardin Cancer Center at Loyola University Medical Center - Maywood
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
District of Columbia
- Washington Cancer Institute at Washington Hospital Center - Washington D.C.
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Georgia
- Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center - Savannah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 515 participants |
| Start Date | 1999-12 |
| Phase | Phase 3 |
What the finished NCT00003325 record still lists
NCT00003325 is an interventional study that assigns participants to a tested intervention. The registered 515 participants enrollment target is mid-sized for trials with a published cap, above the 423-participant average among 17 other Vulvar Cancer trials with a reported enrollment target (22% higher).
The record links to 1 condition, with Vulvar Cancer appearing as the primary indexed condition, and to 1 intervention - of which Sentinel lymph node mapping is the first listed.
NCT00003325 names 20 study sites across 8 states, led by Indiana, Connecticut, California.
Frequently Asked Questions
What is clinical trial NCT00003325 about?
NCT00003325 is a clinical study titled "Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva". RATIONALE: Lymphatic mapping may improve the ability to detect cancer of the vulva. PURPOSE: This phase III trial is studying how well lymphatic mapping works in treating patients with stage I or stage II cancer of the vulva.
What is the current status of trial NCT00003325?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 515 participants. The study started on 1999-12.
What conditions does trial NCT00003325 study?
This clinical trial studies the following conditions: Vulvar Cancer.
What interventions are being tested in trial NCT00003325?
The interventions under investigation include: Sentinel lymph node mapping (PROCEDURE).
Who is sponsoring clinical trial NCT00003325?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003325 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vulvar Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003325's enrollment target sits among peer trials
515 2nd of 17 the highest of 17 other Vulvar Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vulvar Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
RECRUITING · NA
-
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
RECRUITING · Phase 2
-
Image-Guided Gynecologic Brachytherapy
RECRUITING · NA
-
Serial MRI Scans During Radiation Therapy
RECRUITING · NA
-
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05577819 · 515 participants · NA
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
- NCT06804837 · 515 participants · NA
Implement and Test Visual Consent Template and Process
- NCT05933083 · 516 participants · NA
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia